Search

Author/Creator Zucca, Luis Eduardo

1. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 3 (March 2019)

Authors:
Smith, Matthew; Parker, Chris; Saad, Fred; Miller, Kurt; Tombal, Bertrand; Ng, Quan Sing; Boegemann, Martin; Matveev, Vsevolod; Piulats, Josep Maria; Zucca, Luis Eduardo; Karyakin, Oleg; Kimura, Go; Matsubara, Nobuaki; Nahas, William Carlos; Nolè, Franco; Rosenbaum, Eli; Heidenreich, Axel; Kakehi...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 3(2019)
Page Start:
408
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

Authors:
Powles, Thomas; van der Heijden, Michiel S; Castellano, Daniel; Galsky, Matthew D; Loriot, Yohann; Petrylak, Daniel P; Ogawa, Osamu; Park, Se Hoon; Lee, Jae-Lyun; De Giorgi, Ugo; Bögemann, Martin; Bamias, Aristotelis; Eigl, Bernhard J; Gurney, Howard; Mukherjee, Som D; Fradet, Yves; Skoneczna, Iw...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1574
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Issue 3 (March 2022)

Authors:
Smith, Matthew R; Scher, Howard I; Sandhu, Shahneen; Efstathiou, Eleni; Lara, Primo N; Yu, Evan Y; George, Daniel J; Chi, Kim N; Saad, Fred; Ståhl, Olof; Olmos, David; Danila, Daniel C; Mason, Gary E; Espina, Byron M; Zhao, Xin; Urtishak, Karen A; Francis, Peter; Lopez-Gitlitz, Angela; Fizazi, Ka...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 3(2022)
Page Start:
362
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search